OBSV News and Press, ObsEva SA From 12/10/20

PRIMROSE 1 52-week results confirm the sustained efficacy and continued safety of linzagolix (Yselty ® ), with a potential best-in-class high-dose option (200 mg with add-back therapy [ABT]) Show the unique low-dose option (100 mg without ABT) has the potential to add...

Geneva, Switzerland and Boston, MA – December 1, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced that Ernest Loumaye, ...

ObsEva (OBSV) has submitted a Marketing Authorization Application ((MAA)) to the EMA for Yselty (linzagolix 100mg and 200mg) for the management of heavy menstrual bleeding ((HMB)) associated with uterine fibroids. The application is being submitted at this time as both Phase 3 studies, PRIMRO...

If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine fibroids: 100 mg once daily for women with a contraindication to or who prefer to avoid hormonal add-back therapy (ABT) 200 mg once daily with concomitant ...

ObsEva (OBSV) jumps 15% premarket after announcing positive topline results of PROLONG, the Phase 2a proof-of-concept trial of ebopiprant (OBE002) in preterm labor.Ebopiprant is a new, oral and selective prostaglandin F2α, receptor antagonist designed to treat preterm labor b...

Over 50% reduction of pre-term delivery within 48hrs of treatment in singleton pregnancy Maternal, fetal and neonatal safety comparable to placebo Data supports advancement of ebopiprant to Phase 2b dose range finding Geneva, Switzerland and Boston, MA – 16 ...

Geneva, Switzerland and Boston, MA – November 13, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced that Company Management wi...

ObsEva SA (OBSV) has appointed Brian O’Callaghan, to succeed Dr Ernest Loumaye, as Chief Executive Officer and member of the company’s Executive Committee, effective 1 December 2020. Brian O’Callaghan has held senior positions within a number of public and private pharmac...

Geneva, Switzerland and Boston, MA – November 9, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced that ObsEva’s Bo...

ObsEva (OBSV): Q3 GAAP EPS of -$0.49 misses by $0.16.Cash and cash equivalents at September 30, 2020 to $50.6M.Press Release For further details see: ObsEva EPS misses by $0.16